01—Abstract
Summary
Summary of the 10-Q filed May 2, 2024. Cited figures are marked; the original filing is the authoritative source.
Ecolab Inc. reported a strong first quarter for 2024, with net sales increasing by 5% year-over-year to $3.75 billiona, driven by a 5% increase in organic sales.
The company demonstrated significant profit growth, with reported operating income up 47% to $517.9 millionb and net income attributable to Ecolab soaring 77% to $412.1 million. This robust performance was supported by an improved gross margin of 43.3% (up from 38.3% in the prior year) due to lower delivered product costs and effective pricing strategies. The company's strategic focus on efficiency and pricing power appears to be paying off, leading to substantial earnings per share growth.
Ecolab also managed its debt effectively, reducing total debt by approximately $630 millionc in the quarter and maintaining a healthy net debt to EBITDA ratio of 2.2. Looking ahead, Ecolab has agreed to sell its global surgical solutions business for $950 million, which is expected to close in the second half of 2024 and generate a pre-tax gain, further strengthening its financial position and allowing for continued strategic investments.
02—Key points
Key Highlights
- Net sales increased 5% to $3.75 billion, with organic sales also up 5%.
- Reported operating income increased 47% to $517.9 million, and net income attributable to Ecolab grew 77% to $412.1 million.
- Gross margin improved significantly to 43.3% from 38.3% in the prior year, driven by lower costs and strong pricing.
- Diluted EPS increased 74% to $1.43, with adjusted diluted EPS up 52% to $1.34.
- The company reduced its total debt by $630 million during the quarter, ending with $7.5 billion in total debt.
- Cash provided by operating activities was strong at $649.4 million, a significant increase from $198.2 million in the prior year.
- Ecolab announced the sale of its global surgical solutions business for $950 million, expected to close in the second half of 2024.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2024, Ecolab Inc. kept $0.11.
- Revenue$3.75B100.0%
- Cost of revenue−$2.13B56.7%
- Gross profit$1.62B43.3%
- Operating costs−$1.11B29.5%
- Operating income$517.9M13.8%
- Interest, other & tax−$105.8M2.8%
- Net income$412.1M11.0%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2024filed May 2, 2024Financial Statements
Q1 FY2024 against Q1 FY2023
| Line item | Q1 FY2024Q1 FY2023 | Change |
|---|---|---|
| Revenue | $3.75B$3.57B | +5.0% |
| Cost of Revenue | $2.13B$2.21B | −3.5% |
| Gross Profit | $1.62B$1.37B | +18.8% |
| SG&A Expenses | $1.08B$990.30M | +8.8% |
| Operating Income | $517.90M$351.60M | +47.3% |
| Interest Expense | $94.50M$80.10M | +18.0% |
| Net Income | $412.10M$233.40M | +76.6% |
| EPS (Basic) | $1.44$0.82 | +75.6% |
| EPS (Diluted) | $1.43$0.82 | +74.4% |
| Shares Outstanding (Basic) | 285.70M284.60M | +0.4% |
| Shares Outstanding (Diluted) | 287.80M285.90M | +0.7% |
05—Questions
Frequently Asked Questions
What were the main drivers of Ecolab's revenue growth in Q1 2024?
Ecolab's revenue growth in Q1 2024 was driven by a 5% increase in net sales and a 5% increase in organic sales. This growth was fueled by strong performance across several segments, notably Global Institutional & Specialty with double-digit growth, and Global Pest Elimination showing 9% organic sales growth. Pricing actions and volume increases also contributed positively to the sales performance.
How did Ecolab's profitability improve in the first quarter?
Profitability saw a significant improvement due to a 47% increase in reported operating income to $517.9 million and a 77% surge in net income attributable to Ecolab to $412.1 million. This was primarily driven by a substantial improvement in gross margin, which rose to 43.3% from 38.3% in the prior year, attributed to lower delivered product costs and effective pricing strategies. The company also benefited from a lower effective tax rate of 9.2% in Q1 2024 compared to 18.0% in Q1 2023, partly due to discrete tax benefits.
What is the significance of the planned sale of the global surgical solutions business?
The planned sale of the global surgical solutions business for $950 million, expected to close in the second half of 2024, is a significant strategic move. It will generate substantial cash proceeds, which Ecolab expects to record as a pre-tax gain. This transaction will likely strengthen the company's financial position, allowing for continued strategic investments and potentially further capital allocation to shareholders, while allowing Ecolab to focus on its core businesses.
How is Ecolab managing its debt and financial resources?
Ecolab is actively managing its debt, reducing total debt by $630 million in Q1 2024, ending the quarter with $7.5 billion in total debt. The company maintained a healthy net debt to EBITDA ratio of 2.2. Ecolab also generated strong operating cash flow of $649.4 million, indicating robust liquidity. The company has a $2.0 billion revolving credit facility and no outstanding commercial paper, suggesting a solid liquidity position to fund operations, investments, and shareholder returns.
06—Continue